Cws Financial Advisors, LLC Gilead Sciences, Inc. Transaction History

Cws Financial Advisors, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	SELL	$71.58 - $87.29 $242,513 - $295,738	-3,388 Reduced 47.35%	3,767 $275,000
Q4 2023 Feb 08, 2024	SELL	$73.27 - $83.09 $27,036 - $30,660	-369 Reduced 4.9%	7,155 $579,000
Q3 2023 Nov 14, 2023	SELL	$73.94 - $80.67 $443 - $484	-6 Reduced 0.08%	7,524 $563,000
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $10,869 - $12,398	-143 Reduced 1.86%	7,530 $580,000
Q1 2023 May 09, 2023	BUY	$77.31 - $88.08 $15,230 - $17,351	197 Added 2.64%	7,673 $636,000
Q4 2022 Feb 10, 2023	SELL	$62.32 - $89.47 $43,624 - $62,629	-700 Reduced 8.56%	7,476 $641,000
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $4,167 - $4,760	70 Added 0.86%	8,176 $504,000
Q2 2022 Aug 08, 2022	SELL	$57.72 - $65.01 $50,851 - $57,273	-881 Reduced 9.8%	8,106 $501,000
Q1 2022 May 03, 2022	BUY	$57.92 - $72.58 $5,212 - $6,532	90 Added 1.01%	8,987 $534,000
Q4 2021 Feb 15, 2022	BUY	$64.88 - $73.64 $92,648 - $105,157	1,428 Added 19.12%	8,897 $646,000
Q2 2021 Aug 06, 2021	SELL	$63.47 - $69.35 $444 - $485	-7 Reduced 0.09%	7,469 $514,000
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $4,500 - $5,134	75 Added 1.01%	7,476 $483,000
Q4 2020 Feb 12, 2021	SELL	$56.65 - $64.55 $14,898 - $16,976	-263 Reduced 3.43%	7,401 $431,000
Q3 2020 Nov 10, 2020	SELL	$62.1 - $78.08 $3,788 - $4,762	-61 Reduced 0.79%	7,664 $484,000
Q2 2020 Aug 11, 2020	BUY	$72.34 - $84.0 $97,876 - $113,652	1,353 Added 21.23%	7,725 $594,000
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $392,642 - $431,894	6,372 New	6,372 $414,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Cws Financial Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Cws Financial Advisors, LLC with notifications on news.